A carregar...

Biomarkers for immunotherapy in bladder cancer: a moving target

Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the program...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Aggen, David H., Drake, Charles G.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5697433/
https://ncbi.nlm.nih.gov/pubmed/29157296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0299-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!